Woodbrook Group Holdings Inc (WDBG)

[august1991]

Neuro-Hitech, Inc. is a specialty pharmaceutical company focused on developing, marketing and distributing branded and generic pharmaceutical products primarily in the cough and cold markets. The Company's principal business is operated through two subsidiaries: MCR American Pharmaceuticals (MCR) and AMBI Pharmaceuticals, Inc. (AMBI). The Company sells its products domestically through United States based distributors. In June 2008, the Company acquired MCR and AMBI. In January 2014, Neuro-Hitech Inc purchased two leases in Ft. Worth Basin in Texas.



AMBI Company

Company Contact

Headquarters: 11080 Roselle St.
SAN DIEGO, CA 92121
Web Address:
http://www.ambitbio.com

Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company's lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company's second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company's third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.


MCR Company

Company Contact


Headquarters: 24TH FLOOR, 111 HUNTINGTON AVENUE
BOSTON, MA 02199
Web Address:
https://www.mfs.com

MFS Charter Income Trust (the Fund) is a closed-end fund and normally invests in corporate bonds of U.S. and/or foreign issuers, U.S. Government securities, foreign government securities, mortgage-backed and other asset backed securities, and emerging market debt securities. The Fund's investment objective is to seek high current income, but may also consider capital appreciation. The Fund invests in high-yield securities rated below investment grade. Investments in high-yield securities involve greater degrees of credit and market risk than investments in higher-rated securities and tend to be more sensitive to economic conditions. The Fund invests a portion of its assets in asset-backed and/or mortgage-backed securities. The Fund may invest up to 100% of the fund's assets in less than investment grade quality debt instruments.